Targets › MURAA
1 program from 1 company in 4 trials: 2 Phase 4, 2 Phase 3; Infectious disease, Other; next expected readout Sep 2027.
Open in Phaseline: the race on MURAA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Meitheal Pharmaceuticals | Fosfomycin (ZTI-01) UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | MURAA | Phase 4 | Healthy Lactating Women; Infections, Bacterial; Gram Negative Infections; Urinary Tract Infections | Sep 2027 |
Healthy Lactating Women (1) Infections, Bacterial (1) Gram Negative Infections (1) Urinary Tract Infections (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.